Aspen Neuroscience (ASPE) sets $15-$17 IPO range for $150 million Parkinson's cell therapy raise
As seen on the 24/7 Wall St. homepage on October 26, 2026.
Second amendment sets $15-$17 range on a $150 million deal
Aspen Neuroscience penciled in a $15 to $17 range on 9.375 million shares, a roughly $150 million Nasdaq raise for its patient-derived cell therapy work in Parkinson's. Leerink, UBS, Piper Sandler, Stifel and Oppenheimer are running the book, which sets pricing up within days.
Continue ReadingShow less
Aspen Neuroscience has filed a second amendment to its S-1 with the SEC, establishing a formal price range of $15 to $17 per share and putting the total raise at roughly $150 million. Pricing is expected within days, so the window for investors tracking this debut is narrow.
The company is developing patient-derived cell therapy for Parkinson's disease, a field that draws attention precisely because it aims to use a patient's own cells to create a personalized treatment. That approach sits at a relatively early and capital-intensive stage of biotech development, which makes the size and structure of this raise worth watching closely.
Five banks are running the book: Leerink, UBS, Piper Sandler, Stifel, and Oppenheimer. That depth of underwriting syndication on a $150 million deal signals a deliberate effort to broaden institutional distribution ahead of pricing, which shapes aftermarket liquidity once the stock begins trading on Nasdaq.
This is an amended filing, so the company has already gone through at least one round of investor feedback before landing on this range. Whether pricing ultimately comes in at the low, mid, or high end of the $15 to $17 band will be one of the clearest early reads on institutional appetite for the offering.